Hidekazu Hirano

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study.

Tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the Asian subgroup of the RATIONALE-305 study.

Journal: Current medical research and opinion

Published: June 09, 2026

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

Journal: International journal of clinical oncology

Published: May 28, 2026

Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study.

Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study.

Journal: Therapeutic advances in medical oncology

Published: March 21, 2026

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.

Journal: British journal of cancer

Published: March 14, 2026

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study.

Journal: EClinicalMedicine

Published: January 22, 2026

Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.

Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.

Journal: JCO precision oncology

Published: January 15, 2026

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors.

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors.

Journal: Cancer research

Published: January 12, 2026

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Journal: Cancer research

Published: January 12, 2026

Updated Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor (2025).

Updated Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor (2025).

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: December 27, 2025

Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer.

Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer.

Journal: Future oncology (London, England)

Published: December 17, 2025

Conversion Surgery after Chemotherapy in a Stage IV BRAF V600E-Mutated Laterally Spreading Tumor With Neuroendocrine Component.

Conversion Surgery after Chemotherapy in a Stage IV BRAF V600E-Mutated Laterally Spreading Tumor With Neuroendocrine Component.

Journal: DEN open

Published: December 11, 2025

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Journal: Targeted oncology

Published: November 17, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026